

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/724,288
(use as many sheets as necessary)				Filing Date	November 28, 2000
Sheet	1	of	4	First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
				Attorney Docket Number	15270.J-004765US

RECEIVED
CENTRAL FAX CENTER
JUL 20 2007

U.S. PATENT DOCUMENTS*				
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number Kind Code ² (# known)		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	855	7,195,761	03-27-2007	Holtzman et al.
	878	7,189,819	03-13-2007	Basi et al.
	879	7,179,892	02-20-2007	Basi et al.
	880	7,014,855	03-21-2006	Schenk
	881	6,982,084	01-03-2006	Schenk
	886	6,962,984	11-08-2005	Ishiwata et al.
	884	2005/0152878 A1	07-14-2005	Solomon et al.
	882	6,787,139	09-07-2004	Schenk
	849	6,727,349	04-27-2004	LaRosa et al.
	870	2003/0207828 A1	11-06-2003	Ishiwata et al.
	869	2003/0135035 A1	07-17-2003	Shannon
	883	6,582,945	08-24-2003	Raso
	871	2003/0092145 A1	05-15-2003	Jira et al.
	867	5,866,129	02-02-1999	Chang et al.
	860	5,858,981	01-12-1999	Schreiber et al.
	885	5,798,102	08-25-1998	McMichael et al.
	876	5,731,284	03-24-1998	Williams
	868	5,245,015	09-14-1993	Fung et al.

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴			
	853	EP	921 189	B1 01-12-2005		
	842	EP	1 481 992	A2, A3 12-01-2004		
	848	WO	05/026211	A2, A3 03-24-2005		
	847	WO	04/071408	A2 08-26-2004		
	846	WO	04/044204	A2, A3 05-27-2004		
	845	WO	03/072036	A2, A3 09-04-2003		
	854	WO	95/07301	A1 03-16-1995		

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional).
²Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if applicable. *Applicant is to place a check mark here if English language Translation is attached.

61048291

Substitute for form 1449B/PTO				Complete If Known	RECEIVED CENTRAL FAX CENTER
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/724,288
(use as many sheets as necessary)				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
Sheet	2	of	4	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	858	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti- β -Ab antibody," <i>J. Clin. Invest.</i> , 116(3):825-832 (2006).			
	840	BORENSTEIN, S., "New Alzheimer's vaccine to be tested on people soon, Early experiments on mice halted condition; considered safe for humans," <i>Free Press</i> , 7/23/01.			
	832	BROADWELL et al., "Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system," <i>Exp. Neurol.</i> , 120(2):245-263 (1993).			
	859	COMERY et al., "Passive Immunization Against β -Amyloid Leads to Acute Cognition Improvement," <i>Society for Neuroscience</i> , abstract, Washington DC, 11/12-16/05.			
	836	DAS et al., "Reduced effectiveness of Ab β -42 immunotherapy in APP transgenic mice with significant amyloid deposition," <i>Neurobiology of Aging</i> , 22:721-727 (2001).			
	861	DE FELICE et al., " β -Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease," <i>Cell Mol. Neurobiol.</i> , 22(5/6):545-563 (2002).			
	862	DISIS et al., "Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines," <i>Blood</i> , 88(1):202-210 (1996).			
	852	European Search Report of 1/16/07 for European Application 04776252.1-2405.			
	830	FOX et al., "Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease," <i>Brain</i> , 121:1631-1639 (1998).			
	831	FUKUTANI et al., "Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val>Ile) mutation cases: A morphometric investigation," <i>J. Neurologic Sci.</i> , 149:177-184 (1997).			
	873	GEYLIS et al., "Immunotherapy of Alzheimer's disease 9AD): From murine models to anti-amyloid beta 9Ab) human monoclonal antibodies," <i>Autoimmunity Rev.</i> , 5:33-39 (2000).			
	887	IDUSOGIE et al., "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <i>J. Immunology</i> , 164:4178-4184 (2000).			
	834	KALBACK et al., "APP Transgenic Mice Tg2576 Accumulate Ab Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques," <i>Biochemistry</i> , 41:922-928 (2002).			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
Sheet	3	of	4	Attorney Docket Number	15270J-004765US

RECEIVED
CENTRAL FAX CENTER
JUL 20 2007

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	863	KIMCHI et al., "Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using <i>in vivo</i> multiphoton microscopy." <i>J. Neuropathol Exp. Neurol.</i> , 60(3):274-279 (2001).			
	843	KLYUBIN et al., "Anti- \AA Antibodies Prevent Block of Long-Term Potentiation In the CA1 Area of Rat Hippocampus <i>In Vivo</i> by naturally Produced \AA Oligomers." <i>Neurobiology of Aging</i> , 25:S224-S225, abstract P2-004, pages S224-S225 (2004).			
	888	KUBY, J., eds., pages 108-109, 131-132 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).			
	833	KUO et al., "Comparative Analysis of Amyloid- β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains." <i>J. Biol. Chem.</i> , 276(16):12991-12998 (2001).			
	886	MORGAN et al., "The N-terminal end of the C ₂ H domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc _y RII and Fc _y RIII binding." <i>Immuno</i> , 86:319-324 (1995).			
	841	OKIE, S., "Promising Vaccine Targets Ravager of Minds." <i>Washington Post</i> , page A01, 5/8/01.			
	829	PARDRIDGE et al., "The Blood-Brain Barrier: Bottleneck in Brain Drug Development." <i>J. Am. Soc. Exp. Neurotherapeutics</i> , 2:3-14 (2005).			
	850	PCT Search Report of 8/8/06 for application PCT/US2005/045515.			
	872	PCT Search Report of 4/6/06 and Written Opinion of 4/8/06 for application PCT/US04/44093.			
	864	PIERA et al., "Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn)." <i>Int. J. Cancer</i> , 55(1):148-152 (1993).			
	877	PLUCKTHUN, A., "Mono- and Bivalent Antibody Fragments Produced in <i>Escherichia coli</i> : Engineering, Folding and Antigen Binding." <i>Immunological Reviews</i> , 130:151-188 (1992).			
	837	Press Release, "Alzheimer's vaccine developer awarded Potamkin Prize," American Academy of Neurology, 5/7/01.			
	838	ROSENBERG, R. N., "The Potamkin Prize for Pick's, Alzheimer's Disease and Related Disorders," pages 1-5. NO DATE AVAILABLE			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 20, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
				Attorney Docket Number	15270J-004765US
Sheet	4	of	4	RECEIVED CENTRAL FAX CENTER JUL 20 2007	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	865	ROSES, A.D., "Apolipoprotein E alleles as risk factors in Alzheimer's disease," <i>Annu. Rev. Med.</i> , 47:387-400 (1996).			T ²
	851	SALDANHA et al., "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion In cos cells," <i>Molecular Immunology</i> , 36:709-719 (1999).			
	856	SEUBERT et al., "Antibody Capture of Soluble A β does not Reduce Cortical A β Amyloidosis in the PDAPP Mouse," <i>Neurodegenerative Diseases</i> , (2007).			
	828	Signet Laboratories, Inc., Product data sheet for mouse monoclonal clone 6E10, revised 7/13/05.			
	874	SOTO et al., "The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis," <i>Biochem. J.</i> , 314:701-707 (1996).			
	839	TRAVIS, J., "A Vaccine for Alzheimer's Disease?®," <i>Science News Online</i> , 156(2) pages 1-3 downloaded from Internet (1999).			
	857	TRAVIS, J., "Saving the Mind Faces High Hurdles," <i>Science</i> , 309:731-734 (2005).			
	844	UniProtKB/Swiss-Prot entry P18525, pages 1-3 downloaded from http://www.uniprot.org/cgi-bin/uniprot.pl/printable?ac=P18525 on 2/8/97, "HV54_Mouse" (11/190).			
	835	VAN LEUVEN, F., "Single and multiple transgenic mice as models for Alzheimer's disease," <i>Progress in Neurobiology</i> , 61:305-312 (2000).			

Examiner Signature	/Daniel Kolker/	Date Considered	03/18/2009
--------------------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

61048291